Elevance Health Q3 EPS rises to $6.27 and raises 2026 profit outlook
Elevance Health reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% from a year earlier, and diluted earnings per share of $6.27, up 17.9% from $5.32, which included a net non-operating benefit of $1.85 per share. The company raised its full-year 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS guidance to at least $29.00, though the Health Benefits operating gain fell 27.5%. For shareholders, the higher outlook is the main change, while nine-month diluted EPS of $21.01 was down 7.3% from the prior year.
Key points
- Third-quarter operating revenue was $50.4 billion, up 0.7% from $50.1 billion a year earlier.
- Diluted EPS was $6.27 versus $5.32 a year earlier; adjusted diluted EPS was $6.99 versus $6.03.
- Full-year 2026 diluted EPS guidance was raised to at least $22.00; adjusted diluted EPS guidance was raised to at least $29.00.
- Health Benefits operating gain fell 27.5% to $0.4 billion, and a $1.72 quarterly dividend was declared for payment on December 18, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.